[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attention-deficit-hyperactivity-disorder-adhd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attention-deficit-hyperactivity-disorder-adhd":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,45,75,98,128,153,174,201,232,255,282,309,332,350,373,401,420],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100635455","a-random-controlled-trial-of-home-based-digital-therapy-for-treating-adhd-in-children-100635455",false,"NCT07552909","A Random Controlled Trial of Home-based Digital Therapy for Treating ADHD in Children","Randomized Controlled Study on Home-Based Digital Therapy Intervention for School-Aged Children With Attention Deficit Hyperactivity Disorder Based on Brain-Controlled Games","Inclusion Criteria:\n\n* Children aged 7 years 0 months to 11 years 11 months\n* Clinical diagnosis of ADHD made by a child psychiatrist at the attending level or above\n* Wechsler Intelligence Scale for Children (WISC) Full Scale IQ (FSIQ) above 85\n* Children who have been diagnosed with ADHD but have not received any intervention (newly diagnosed within the last month or not having taken medication for at least 4 weeks)\n* Informed consent must be obtained from the patient\u002Fguardian and from participants\n\nExclusion Criteria:\n\n* Auditory or visual illness or disorder\n* Inability to use software (e.g., color blindness, impaired hand function, or disability)\n* Comorbid oppositional defiant disorder, autism spectrum disorder, pervasive developmental disorder, tic disorders, or other neurodevelopmental disorders\n* Other mental illnesses such as organic mental disorders, schizophrenia, bipolar disorder, or depressive disorders\n* Attention deficit disorder caused by organic neurological diseases or other organic diseases\n* Previous regular ADHD medication use as prescribed by a doctor, but without efficacy\n* Past or present gaming addiction\n* Previous neurofeedback-like \"brain control game\" interventions\n* Previous physical therapy such as magnetic stimulation.","ALL","7 Years","11 Years",{"count":20,"type":21},146,"ESTIMATED","INTERVENTIONAL",[24],"NA","Explore the interventional effects of neurofeedback games on school-aged children with mild to moderate ADHD, with the aim of providing evidence-based new methods for intervening in the core symptoms of ADHD in children.",[27],"Attention Deficit Hyperactivity Disorder (ADHD)",[29,30,31],"Attention deficit hyperactivity disorder","Randomized Controlled","Digital Brain-controlled","RECRUITING","2026-04-22",{"date":35,"type":36},"2026-04-27","ACTUAL",{"date":38,"type":36},"2025-08-24",{"date":40,"type":21},"2026-05-31",{"name":42,"class":43},"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100578352","examination-of-the-dynamic-relationships-of-sleep-physical-activity-and-circadian-rhythmicity-with-neurobehavioral-heterogeneity-in-adhd-100578352","NCT06810180","Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD","ADHD Clinical Group. Meet criteria for attention deficit\u002Fhyperactivity disorder (ADHD) according to DSM-5 criteria.\n\nExclusion Criteria:\n\nPrematurity Prenatal exposure to alcohol or other substances Traumatic brain injury Co-occurring neurodevelopmental disorders (e.g., autism spectrum disorder, intellectual disability) Anxiety\u002Fmood disorders Active psychosis Bipolar disorder Conduct disorder Currently taking longer acting psychotropic medications that cannot be discontinued the day before research appointments\n\nControl Group. Does not meet criteria for psychological or neuropsychological disorders Does not meet criteria for intellectual disability Does not meet criteria for a learning disorder\n\nExclusion Criteria:\n\nPrematurity Prenatal exposure to alcohol or other substances Traumatic brain injury Currently taking medications that cannot be discontinued the day before research appointments",true,"8 Years","12 Years",{"count":55,"type":21},200,[24],"Attention deficit\u002Fhyperactivity disorder (ADHD) can present differently in individuals, with some individuals having difficulty with attentional control, hyperactivity, impulsivity, emotion dysregulation, and\u002For neurobehavioral functioning. The factors contributing to these different presentations remain unclear, but altered patterns of physical activity, sleep, and circadian rest\u002Factivity rhythms may play a key role.\n\nThe goal of this study is to leverage wearable technology (i.e., a wristband) to investigate the relationships between physical activity during the day, sleep patterns and disturbances, and 24-hour circadian rest\u002Factivity rhythms with differences in ADHD symptoms, emotion dysregulation, and related brain and behavioral features of attention-deficit\u002Fhyperactivity disorder (ADHD). The investigators hope this study will help improve assessment and intervention for individuals with ADHD by understanding how these factors relate to ADHD symptom expression and associated brain differences in ADHD.\n\nParticipants taking stimulant medication must withhold stimulant medication 24 hours before their research appointment and the morning of their research appointment. Stimulant medication may be restarted after the appointment is complete.\n\nParticipation in this study will require children to complete an initial 2-hour research appointment, two (2) weeks of activity and sleep monitoring at home using a wearable wristband and answering questions sent to a smartphone, and a second 4-hour research appointment after the 2-week period.\n\nDuring the first research appointment, children will complete a cognitive assessment and a practice magnetic resonance imaging (MRI) scan. Parents\u002Flegal guardians will participate in the 30-45-minute sleep device training session with one of the research staff.\n\nDuring the two weeks of activity\u002Fsleep monitoring at home, parents and children will answer questions about their sleep routine, ADHD symptoms, and emotional responding each morning and evening. Parents will be asked to install a questionnaire application on their smartphone. A prompt will be sent to their smartphone multiple times per day reminding parents to complete the brief assessment.\n\nAfter the 2-week period, children will complete a 4-hour research appointment. During this research appointment, children will complete a 60-minute MRI scan and computer-based activities that assess cognitive skills, reward-based decision-making, and frustration tolerance. At the end of the research appointment, children will return the device to our research team. Parents may delete the questionnaire application from their phone at the end of the research appointment.\n\nParticipation will also require parents\u002Flegal guardians to complete questionnaires about their child. Questionnaires will be provided to the primary caregiver by email or at the beginning of their child's first research appointment. Parents agree to complete and return the questionnaires within one month of their child's research appointment.\n\nParents may be provided with additional questionnaires to give to their child's primary schoolteacher. This information is collected to better understand children's abilities, behavior, strengths, and weaknesses.\n\nThere are minimal risks associated with this study. Risks include fatigue, boredom, and mild discomfort.\n\nThere is no cost to participating in this study.\n\nThere is no direct benefit to participants for participating in this study.",[27,59,60],"Sleep","Physical Activity",[62,63,64],"ADHD","Circadian Rhythms","Ecological Momentary Assessment (EMA)","2026-03-06",{"date":67,"type":36},"2026-03-09",{"date":69,"type":36},"2025-06-17",{"date":71,"type":21},"2031-03-31",{"name":73,"class":43},"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100628289","effects-of-probiotics-on-the-gut-brain-axis-in-children-100628289","NCT07459699","Effects of Probiotics on the Gut-brain Axis in Children","Randomised, Placebo-controlled Pilot Study to Assess the Effects of Probiotics on the Gut-brain Axis in Children With Attention Deficit Hyperactivity Disorder","Inclusion Criteria:\n\n* Males and females aged 8 - 11 years\n* With mild ADHD symptoms\n* Patient and parents (legal representatives) able and willing to participate in the research by complying with the protocol procedures\n\nExclusion Criteria:\n\n* Metabolic disorder\n* Severe chronic disease\n* GI disorders found to be inconsistent with the conduct of the study by the investigator\n* Neurological disorder involving central function (e.g., intellectual disability, autism spectrum disorder, epilepsy, narcolepsy)\n* Currently treated with a medication with primary central nervous system activity or major psychiatric condition requiring hospitalization\n* With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredients\n* Having taken prebiotic or probiotic treatment in the month prior to inclusion, or having taken antibiotics for more than one week in the 3 months prior to inclusion,\n* Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,\n* Parents (legal representatives) presenting a psychological or linguistic incapability to sign the ICF,\n* Parents (legal representatives) impossible to contact in case of emergency.",{"count":83,"type":21},80,[24],"The effect of probiotics on the gut-brain axis in children with attention deficit hyperactivity disorder will be studied.",[27],"NOT_YET_RECRUITING","2026-03-05",{"date":90,"type":36},"2026-03-10",{"date":92,"type":21},"2026-03",{"date":94,"type":21},"2027-10",{"name":96,"class":97},"Probi AB","INDUSTRY",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100581696","phase-4-the-team-study---treatment-efficacy-for-autismattention-using-mixed-amphetamine-100581696","NCT06853665","The TEAM Study - Treatment Efficacy for Autism\u002FAttention Using Mixed Amphetamine","A Pharmaco-Imaging Trial of Mixed Amphetamine Salts for the Treatment of ADHD in Intellectually-intact Youth With Autism Spectrum Disorder","Inclusion Criteria:\n\nParticipants with Autism Spectrum Disorder (ASD) and Attention Deficit\u002FHyperactivity Disorder (ADHD)\n\n* Male or female participants between 8 and 18 years of age (inclusive).\n* Participant intact communicative language, as clinically determined.\n* Meet DSM-5-TR diagnoses of ADHD and ASD as established by clinical diagnostic interview.\n* At least moderate current ADHD symptoms severity (Clinician-rated ADHD-RS score ≥28 and ADHD-CGI-S of ≥4)\n* At least moderate current ASD symptoms severity (SRS-2 raw score ≥85 and ASD-CGI-S of ≥4).\n* Participants with disruptive behavior disorders, mood and anxiety disorders will be allowed to participate in the study provided they do not meet any exclusionary criteria.\n* Participant must be on a stable regimen of psychotropic treatment.\n* Participants must understand the nature of the study. Participants must be deemed not to have impaired decision-making capacity and must have the capacity to provide direct informed consent. Participants must sign an IRB-approved informed consent form before initiation of any study procedures.\n* Participants must have a level of understanding sufficient to communicate with the investigator and study coordinator and be willing to cooperate with all tests and examinations required by the protocol.\n* Participant weight is above the 5th percentile and below the 95th percentile, per CDC child BMI categories (https:\u002F\u002Fwww.cdc.gov\u002Fobesity\u002Fbasics\u002Fchildhood-defining.html)\n\nTypically Developing Control Participants\n\n* Age-, sex-, \\& IQ-matched with ASD participants.\n* No significant traits of ASD as screened by SRS-2 (raw score \\\u003C60).\n* No significant ADHD symptoms as screened by parent-rated ADHD-RS (score \\\u003C18)\n* No significant psychopathology as screened on the CBCL (Subdomain T-scores \\\u003C60).\n* Participant weight is above the 5th percentile and below the 95th percentile, per CDC child BMI categories (https:\u002F\u002Fwww.cdc.gov\u002Fobesity\u002Fbasics\u002Fchildhood-defining.html)\n\nExclusion Criteria (all participants except where noted):\n\n* Impaired intellectual capacity as determined either by history of intellectual disability or as assessed, in ASD participants only, during the clinical evaluation and determination will be based on intact communicative language, intellectual performance, and ability to take personal care.\n* Participant is unable to communicate due to delay in, or total lack of, spoken language development (grossly impaired language skills)\n* Participants with a poor command of the English language and\u002For require an interpreter.\n* Participant is unable to swallow pills (ASD participants only)\n* Participants with a medical condition or treatment that will either jeopardize subject safety or affect the scientific merit of the study, including:\n* Pregnant or nursing females or females with a positive Beta-HCG pregnancy test.\n* Uncorrected hypothyroidism or hyperthyroidism.\n* History of non-febrile seizures within last 1 month without a clear and resolved etiology.\n* Diagnosis of glaucoma (ASD participants only)\n* History of renal or hepatic impairment.\n* Serious systemic illness\n* Personal history of cardiac disease or a family history of non-geriatric cardiac disease or death (ASD only)\n* Participants with known medical risk factors (e.g., known untreated hypertension, arrhythmia, premature family history of sudden death) and active symptoms that, in the investigators' opinion, place them at risk for untoward adverse effects (ASD only)\n* Participants with an unstable medical condition (that requires clinical attention).\n* Clinically unstable psychiatric conditions or judged to be at serious safety risk to self (suicidal risk) or others (within past 30 days).\n* Participants currently (within past 30 days) experiencing significant symptom severity of major psychiatric disorders as clinically determined.\n* Active symptoms of anorexia or bulimia nervosa\n* History of substance use (except nicotine, recreational use of THC, or caffeine) within past 3 months\n* Initiation of a new psychosocial intervention within 4 weeks prior to randomization.\n* Participants treated with a psychotropic medication(s) on a dose that has not been stable for at least 4 weeks prior to study baseline.\n* Participants receiving treatment with an MAOI within two weeks prior to receiving study medication.\n* Participants receiving treatment with stimulant class of medication. (ASD participants on a stable treatment of non-stimulant ADHD treatment medications will be included.)\n* History of non-response of ADHD symptoms to amphetamine salt as defined by being on therapeutic dose for at least 1 week. (ASD only)\n* Subjects with previous poor response or poor tolerability to mixed amphetamine salts (ASD only)\n* History of allergic reaction to amphetamine or dextroamphetamine (for ASD participants only)\n* Investigator and his\u002Fher immediate family, defined as the investigator's spouse, parent, child, grandparent, or grandchild.\n* Contraindications to MRI scanning as described in the MIT MRI Screening Checklist. Subjects can choose a security object (e.g., fidget toy, stuffed animal, or blanket) that is MRI-safe and provided by the imaging center, in the scanner to help with possible anxiety they might experience due to the scanning. Typically developing control subjects with contraindications to MRI scanning will not be eligible to participate in the trial.","18 Years",{"count":107,"type":21},196,[109],"PHASE4","The investigators are conducting a 10-week brain imaging and medication study. They are doing the research to study the response of Attention-Deficit\u002F Hyperactivity Disorder (ADHD) in youth with Autism Spectrum Disorder (ASD) on extended-release formulation of mixed amphetamine salts (MAS) (also know as Adderall XR). The investigators also want to find out if taking MAS has any effect on the brains of children and adolescents with ADHD and ASD. This study will help researchers better understand how the use of MAS to treat ADHD effects children and adolescents with ASD. The investigators will compare MAS to a placebo. The placebo will look exactly like the MAS capsules but will contain no MAS. During this study, participants may get a placebo instead of MAS. Placebos are used in research studies to see if the study results are due to the study drug or due to other reasons.\n\nParticipants with ASD and ADHD will complete 4-weeks of treatment with the study medication or placebo. They will complete bi-weekly study visits virtually via a telemedicine platform with the study doctor and complete questionnaires. On alternating weeks, they will meet with a Massachusetts General Hospital (MGH) study team member to discuss medication adherence and potential side effects. Participants will have the option to attend all study visits in-person if participants prefer. They will also complete baseline and endpoint Magnetic Resonance (MR) scan visits at Massachusetts Institute of Technology (MIT). During the MR Scan visits, they will complete a series of tasks to measure inattention, impulsivity, reward sensitivity, decision-making, and working memory.\n\nParticipants without ADHD or ASD will complete eligibility screening with MGH. If eligible, they will be invited to baseline and endpoint MR scan visits at MIT. During the MR Scan visits, they will complete a series of tasks to measure inattention, impulsivity, reward sensitivity, decision-making, and working memory.",[27,112,113],"Autism","Autism Spectrum Disorder",[62,115,112,116,117,118,119,120],"Attention","Treatment","Pharmaco-imaging","Imaging","MRI","Drug Study",{"date":65,"type":36},{"date":123,"type":36},"2026-02-01",{"date":125,"type":21},"2030-02-01",{"name":127,"class":43},"Gagan Joshi",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":44},"100589943","improving-adhd-teen-driving---virtual-reality-100589943","NCT06960980","Improving ADHD Teen Driving - Virtual Reality","Inclusion Criteria:\n\n1. Aged 16-19.\n2. Teens will meet DSM ADHD criteria for ADHD-Predominantly Inattentive Presentation or ADHD-Combined Presentation based on the K-SADS interview.\n3. Possess a valid driver's license and regularly spend at least 3 hours per week engaged in unsupervised driving.\n4. IQ ≥80 as measured by the Kauffman Brief Intelligence Scale - Second Edition (KBIT-2).\n5. Parent willing to participate.\n\nExclusion Criteria:\n\n1. On ADHD medication that cannot be washed out on assessment days.\n2. Drug or alcohol dependence based on self-report on the Simple Screening Instrument for Alcohol and Other Drugs survey.\n3. On psychotropic or neuroleptic medications.\n4. At-risk for motion sickness in the driving simulator or in virtual reality.\n5. History of moderate to severe head trauma, neurological disorder, or any other organic disorder that could possibly affect brain function.\n6. Cannot see the secondary task stimuli without the use of glasses (contacts acceptable).","16 Years","19 Years",{"count":137,"type":21},204,[24],"Teens with Attention-Deficit\u002FHyperactivity Disorder (ADHD) have high rates of negative driving outcomes, including motor vehicle crashes, which may be caused by visual inattention (i.e., looking away from the roadway to perform secondary tasks). Two versions of a driving intervention that trains teens to reduce instances of looking away from the roadway will be tested in teens with ADHD.",[27],[142,143],"Visual attention","Automobile Driving","2026-02-20",{"date":146,"type":36},"2026-02-23",{"date":148,"type":36},"2025-09-11",{"date":150,"type":21},"2029-08-31",{"name":152,"class":43},"Children's Hospital Medical Center, Cincinnati",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":105,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100625719","virtual-reality-supported-rehabilitation-for-childrens-executive-and-metaphonological-skills-100625719","NCT07426289","Virtual Reality Supported Rehabilitation for Children's Executive and Metaphonological Skills","Evaluating the Effectiveness of a Virtual Reality Rehabilitation System (VRRS) Intervention on Executive Function Enhancement and Monitoring of Metaphonological Skills in ADHD Children","Inclusion Criteria:Inclusion Criteria:\n\n* Children aged 8 to 12 years\n* Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)\n* Attending 3rd, 4th, or 5th grade of primary school\n* IQ greater than 70 (based on recent cognitive assessment)\n* Presence of executive function impairment and\u002For metaphonological difficulties\n* Availability of a baseline neuropsychological assessment (T0) completed within the last 3 months\n* Parental consent obtained\n\nExclusion Criteria:\n\n* Comorbid diagnosis of specific learning disorders (SLD)\n* Neurological, genetic, or psychiatric comorbidities other than ADHD\n* Uncorrected sensory impairments (vision or hearing)\n* Lack of informed consent","6 Years",{"count":162,"type":21},50,[24],"Executive functions and metaphonological skills are closely interconnected in supporting language development and learning processes.Investigating this relationship could offer new insights into how executive and metaphonological skills interact, supporting the development of integrated intervention strategies targeting both cognitive and linguistic domains.\n\nThis study aims to evaluate the effectiveness of a rehabilitation intervention using a virtual reality system (VRRS) in enhancing executive functions and monitoring metaphonological skills in children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD).The aim is to explore whether a semi-immersive digital cognitive training protocol can lead to measurable improvements in executive functions, and whether such improvements are associated with gains in metaphonological skills.\n\nParticipants will present deficits in executive functions and metaphonological skills and will undergo pre- and post-intervention assessments. These assessments include standardized neuropsychological and speech-language pathology tools designed to detect impairments in attention, inhibition, working memory, phonological awareness, and behavior in home and school settings.",[27],"2026-02-16",{"date":146,"type":36},{"date":169,"type":21},"2026-03-31",{"date":171,"type":21},"2030-12-31",{"name":173,"class":43},"IRCCS Centro Neurolesi Bonino Pulejo",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":181,"minAge":4,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":44},"100607506","l-theanine-and-paraxanthine-for-cognitive-improvement-in-adults-with-adhd-and-asd-100607506","NCT07189442","L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD","Combining L-theanine and Paraxanthine for Transient Improvement of Cognitive Deficits Among Patients With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Series of Translational Pilot Neuroimaging Studies","Inclusion Criteria:\n\nAdults (18+ years) diagnosed by a physician (per self-report) with ADHD or ASD\n\n\\* Participants with a dual diagnosis and ASD and ADHD will be recruited but will only be included in the ASD group - their concurrent ADHD diagnosis will be included as an additional variable in exploratory analyses\n\nExclusion Criteria:\n\n1. Subjects with gross visual or auditory impairments that might limit their ability to perform neuropsychological tasks\n2. Inability to read and follow written instructions\n3. Physical, neurological, intellectual, or psychiatric impairments (except ADHD or ASD) that could affect cognitive and motor functions\n4. Subjects on medications including antidepressants and antipsychotics that may affect performance in the tasks\n5. Subjects on medications that are likely to interact with the administered substances, including regular intake of medication that could alter visual, auditory, cognitive, or motor functions (except stimulants)\n6. History of head injury resulting in loss of consciousness\u002Fhistory of brain surgery\n7. Subjects who have developed adverse effects when caffeine\u002Fparaxanthine \u002FL-theanine\u002Fcorn starch (will be in placebo) containing products were consumed\n8. Subjects who are unwilling or unable to refrain from intake of L-theanine\u002F caffeine\u002F paraxanthine containing food or beverages within the 24 hours prior to each study visit\n9. Intake of drugs containing caffeine, other phosphodiesterase inhibitors, or adenosine receptor blockers within the past 3 months\n10. Intake of medications known to have pharmacological interactions with paraxanthine within the past 3 months\n11. Current\u002Fpast diagnosis of tics or other forms of dyskinesia\n12. History of headache, drowsiness, anxiety, insomnia, or nausea following intake of caffeine or caffeine-containing beverages\n13. Current\u002Fpast history of smoking and\u002For alcohol or drug abuse\n14. Subjects with absolute contraindications to undergo MRI after being screened by the TTNI safety screening sheet (Appendix)\n15. Unwillingness or inability to entirely refrain from the use of electronic devices during study visits\n16. Unwillingness or inability to follow written, on-screen, and verbal instructions given by the study team.","MALE",{"count":183,"type":21},24,[24],"This pilot study will test whether combining L-theanine and paraxanthine improves sustained attention, inhibitory control, and overall cognition in adults with ADHD and ASD. Two parallel randomized, single-blinded, repeated-measures crossover trials will be conducted. Participants will complete neuropsychological testing, fMRI scanning, and self-report measures following administration of the L-theanine-paraxanthine combination compared to placebo.",[27,187],"Autism Spectrum Disorder (ASD)",[62,189,190,191,112],"Attention Deficit Hyperactivity Disorder","ASD","Autism spectrum disorder","2026-02-04",{"date":194,"type":36},"2026-02-05",{"date":196,"type":36},"2025-10-01",{"date":198,"type":21},"2026-06-01",{"name":200,"class":43},"Texas Tech University Health Sciences Center",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":212,"phases":4,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":44},"100533095","pharmacogenomics-of-stimulant-treatment-response-100533095","NCT06221358","Pharmacogenomics of Stimulant Treatment Response","Pharmacogenomics of Stimulant Treatment Response in Children and Adolescents With Attention-Deficit\u002F Hyperactivity Disorder","PGx-STaR","Inclusion Criteria:\n\nPatients will be eligible for participation if all the following are true.\n\n* Aged 6 - 24 years.\n* Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).\n* Primary diagnosis of ADHD (all types).\n* Starting Methylphenidate (excluding immediate release forms) treatment.\n\nExclusion Criteria:\n\nPatients will be excluded from participation if any of the following are true.\n\n* Co-occurring psychotic, bipolar or eating disorders.\n* Significant risk of suicide.\n* An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics\u002FTourette disorders.\n* Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use.\n* Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate\u002Fchange these types of therapies during the study\n* History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.","24 Years",{"count":211,"type":21},400,"OBSERVATIONAL","The \"Pharmacogenomics of Stimulant Treatment Response\" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit\u002Fhyperactivity disorder (ADHD).",[215],"Attention-Deficit\u002F Hyperactivity Disorder (ADHD)",[217,218,62,219,220,221,222],"Children","Adolescents","Pharmacogenetics","Neurology","Psychostimulants","Methylphenidate","2025-11-27",{"date":225,"type":36},"2025-12-05",{"date":227,"type":36},"2024-04-01",{"date":229,"type":21},"2028-12-31",{"name":231,"class":43},"University of Calgary",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":105,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":253,"locationsCount":4},"100604839","transcranial-photobiomodulation-with-multiple-interventions-in-children-with-attention-deficithyperactivity-disorder-100604839","NCT07154732","Transcranial Photobiomodulation With Multiple Interventions in Children With Attention-Deficit\u002FHyperactivity Disorder","Inclusion Criteria:\n\n1. Age between 6 and 18 years;\n2. Clinically diagnosed with ADHD by a psychiatrist;\n3. Confirmed by the researcher (child psychiatrist) to meet the diagnostic criteria for Attention-Deficit\u002FHyperactivity Disorder as outlined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);\n4. M.I.N.I. KID interview shows only ADHD, with no other comorbidities;\n5. Able to cooperate with transcranial photobiomodulation.\n6. The participant and their guardian fully understand the study procedures and content and agree to participate in the study, signing the informed consent form.\n\nExclusion Criteria:\n\n1. Diagnosis of other severe mental illnesses, such as schizophrenia or bipolar disorder;\n2. Presence of severe physical diseases or conditions, such as significant intracranial lesions, thyroid disorders, epilepsy, congenital heart disease, severe hematologic disorders, systemic lupus erythematosus, auditory or visual impairments, etc.;\n3. Presence of significant structural brain abnormalities on imaging studies;\n4. Presence of severe neurological diseases with a clear family history or potential risk;\n5. Presence of metal implants or a pacemaker, or holes or fractures in the skull;\n6. Currently undergoing other ADHD treatments (e.g., methylphenidate or other pharmacological treatments, behavioral therapy, etc.) or has discontinued such treatments for less than 2 weeks;\n7. Raven's Progressive Matrices IQ score \\\u003C 85.",{"count":239,"type":21},54,[24],"To investigate the therapeutic efficacy of transcranial photobiomodulation (tPBM) with multiple interventions in children and adolescents with attention-deficit\u002Fhyperactivity disorder (ADHD). The study evaluates intervention effects at Magnetic Resonance Imaging, electrophysiological, Visual Search Task, cognitive-behavioral, and clinical symptom levels, aiming to identify the optimal clinical treatment regimen for ADHD patients.",[27],[244,245,27,246],"transcranial Light Stimulation (tLS)","transcranial photobiomodulation (tPBM)","Electroencephalography (EEG)","2025-09-30",{"date":249,"type":36},"2025-10-06",{"date":196,"type":21},{"date":252,"type":21},"2027-01-30",{"name":254,"class":43},"Qilu Hospital of Shandong University",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":51,"sex":16,"minAge":262,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":212,"phases":4,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":280,"locationsCount":44},"100606838","prediction-of-adhd-in-children-using-pedobarographic-and-postural-data-100606838","NCT07180758","Prediction of ADHD in Children Using Pedobarographic and Postural Data","Prediction of Attention Deficit Hyperactivity Disorder (ADHD) in Middle School Children Using Machine Learning With Pedobarographic Data","Inclusion Criteria:\n\n* Students attending a middle school located in Eyüpsultan district\n* Informed consent obtained from their parents\n* Students enrolled in full-time education\n* Children with age-appropriate motor development skills.\n\nExclusion Criteria:\n\n* Children who have undergone orthopedic interventions due to lower extremity or spinal deformities\n* Children with congenital or acquired neuromuscular disorders\n* Children with significant visual or auditory impairments\n* Children with systemic diseases","10 Years","14 Years",{"count":265,"type":21},100,"The aim of this study is to investigate the potential of postural control and plantar pressure data in predicting Attention Deficit Hyperactivity Disorder (ADHD) in middle school students using machine learning methods. A total of 100 students will participate, including those identified with symptoms of ADHD and healthy controls. Participants will undergo non-invasive biomechanical assessments, including pedobarographic foot pressure measurement and mobile posture analysis. Behavioral data will be collected using DSM-IV-based rating scales developed by Atilla Turgay, completed separately by parents, teachers, and caregivers. All data will be used to develop predictive models using algorithms such as random forest, logistic regression, and support vector machines. The study is observational and cross-sectional.",[27],[269,270,271,272,273],"Attention Deficit Disorder with Hyperactivity","Artificial Intelligence","Posture","Machine Learning","child","2025-09-16",{"date":276,"type":36},"2025-09-18",{"date":278,"type":36},"2025-05-09",{"date":92,"type":21},{"name":281,"class":43},"Biruni University",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":297,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":44},"100602293","phase-4-pharmacokinetics-of-methylphenidate-in-adult-patients-with-attention-deficit-hyperactivity-disorder-100602293","NCT07121621","PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit \u002FHyperactivity Disorder","PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit \u002FHyperactivity Disorder: Comparison Between Patients With and Without OBesity","PHACYLOB","Inclusion Criteria:\n\n* Adults aged 18 and over\n* Diagnosis of ADHD by a psychiatrist, based on DSM-5 criteria (ADHD mixed form, predominantly inattentive or predominantly hyperactive\u002Fimpulsive)\n* Treatment with methylphenidate LP (Ritaline) with a stable dosage for at least two weeks.\n* BMI inclusion criteria: (1) for obese group: BMI ≥ 30 kg\u002Fm2; (2) for non-obese group: BMI \\\u003C 30 kg\u002Fm2.\n* Participant affiliated to a social security scheme\n* Written consent signed by participant\n\nExclusion Criteria:\n\n* Contraindications to methylphenidate treatment\n* Treatment with an oral or nasal decongestant vasoconstrictor; association with a non-selective MAOI antidepressant.\n* Treatment with a proton pump inhibitor within the last 2 weeks.\n* Severe cognitive impairment (clinical evaluation)\n* Severe alcohol use disorder, i.e. at least 6 DSM-5 criteria for substance use disorder (clinical evaluation)\n* Known prior renal impairment\n* Pregnant or breast-feeding women\n* Female patients of childbearing age without at least one acceptable contraceptive method (see definition in Appendix 1)\n* Patients under legal protection\n* Inability of the patient to self-assess the intensity of ADHD symptoms",{"count":291,"type":21},30,[109],"PHACYLOB PHArmaCokinetics of methYLphenidate in adult patients with Attention-Deficit Hyperactivity Disorder (ADHD) : comparison between patients with and without OBesity.\n\nIts aim is to determine whether, for a comparable treatment dose, there are differences in the pharmacokinetic of methylphenidate between ADHD patients with obesitý and ADHD patients but without obesitý. More specifically, we will assess whether blood concentrations of methylphenidate (MPH; long acting form) are significantly higher or lower in either group at different times of the day.\n\nTo meet this objective, we are conducting this pharmacokinetic clinical trial with blood sampling and repeated clinical measurements just prior to MPH administration (= at T0) and then, at different times after administration, i.e. at times (T): T 30 minutes, T 1 hour, T2h, T3h, T4h, T6h, T8h after MPH administration. As far as MPH is concerned, this is the usual treatment. However, we may hypothesize that the distribution in the body may differ according to weight: hence the interest of this study",[27,295,222,296],"Obesity (Body Mass Index &Amp;Amp;gt;30 kg\u002Fm2)","Obesity &Amp; Overweight",[222,27,298,299],"Obesity","Pharmacokinetics","2025-08-12",{"date":302,"type":36},"2025-08-13",{"date":304,"type":21},"2025-09-01",{"date":306,"type":21},"2026-09-02",{"name":308,"class":43},"University Hospital, Tours",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":44},"100587318","phase-3-a-long-term-trial-of-eb-1020-in-adult-patients-with-adhd-100587318","NCT06926829","A Long-term Trial of EB-1020 in Adult Patients With ADHD","A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Trial to Evaluate the Safety and Efficacy of Long-term Administration of EB-1020 Once Daily QD XR Capsules in Adults With Attention-deficit\u002FHyperactivity Disorder","Inclusion Criteria:\n\n* Participants who completed the treatment period andfollow-up period in the preceding double-blind parent Trial (Trial 405-102-00112) and did not meet the criteria for discontinuation of the investigational medicinal product (IMP).\n* Participants who have not been found to have major problems with trial requirements, such as compliance with the IMP, in the preceding double-blind parent trial.\n\nExclusion Criteria:\n\n* Participants who are pregnant or breastfeeding or test positive for pregnancy on baseline visit.\n* Participants who started prohibited concomitant medications\u002Ftherapies for ADHD or other comorbidities at the end of the follow-up period of the preceding trial, or participants for whom starting treatment is deemed beneficial.\n* Participants who have a significant risk of committing suicide in the opinion of the investigator or subinvestigator, or based on the following evidence:\n\n  * Active suicidal ideation as evidenced by an answer of \"yes\" on Questions 4 or 5 on the section of suicidal ideation on the since last visit version of the Columbia-Suicide Severity Rating Scale (C-SSRS) in the preceding double-blind parent trial or\n  * Reported suicidal behavior\n* Participants who were found to have serious or severe adverse events that were judged to be related to the IMP in the preceding double-blind parent trial.\n* Participants who test positive for drugs or alcohol in a urine test on baseline visit.","55 Years",{"count":318,"type":21},180,[320],"PHASE3","The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan",[27],"2025-07-30",{"date":325,"type":36},"2025-08-03",{"date":327,"type":36},"2025-06-25",{"date":329,"type":21},"2027-12",{"name":331,"class":97},"Otsuka Pharmaceutical Co., Ltd.",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":316,"enrollmentInfo":339,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":349,"locationsCount":44},"100587645","phase-2-evaluation-of-the-efficacy-and-safety-of-eb-1020-in-adult-adhd-patients-100587645","NCT06931080","Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients","A Phase 2\u002F3, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial to Evaluate the Efficacy and Safety of EB-1020 Once Daily QD XR Capsules Administered Orally at Low or High Dose in Adults With Attention-deficit\u002FHyperactivity Disorder","Inclusion Criteria:\n\n* Participants diagnosed primarily with ADHD (excluding other specified or unspecified attention-deficit\u002Fhyperactivity disorder) according to DSM-5 criteria, based on information collected through interviews using the Japanese version of the Conners' Adult ADHD Diagnostic Interview for DSM-IVTM (CAADID).\n* Participants with an AISRS total score meeting the following criteria:\n\n  * Not receiving medication treatment for ADHD: 28 points or higher\n  * Receiving medication treatment for ADHD: 22 points or higher\n\nExclusion Criteria:\n\n* Participants who are pregnant or breastfeeding, and those who test positive for pregnancy at screening.\n* Participants have a current comorbid psychiatric disorder that either could be expected to require treatment with medications prohibited in this trial, or to confound efficacy or safety assessments. Examples include, but are not limited to, psychotic disorder (current or lifetime), bipolar disorder (current or lifetime), generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, a current major depressive episode, or posttraumatic stress disorder, as established by the MINI.\n* Participants diagnosed with a personality disorder according to DSM-5 criteria.\n* Participants diagnosed with autism spectrum disorder according to DSM-5 criteria.\n* Participants diagnosed with intellectual disability and an IQ score below 70.\n* Participants who, in the judgment of the principal or sub-investigator, or based on the following criteria, are at significant risk of suicide:\n\n  • Clear suicidal ideation or a history of suicidal behavior (within the past 6 months) as indicated by a \"\"yes\"\" answer to questions 4 or 5 in the suicidal ideation section of the C-SSRS Baseline\u002FScreening version at screening.\n* Participants who have a current or past episode of substance-related disorders (excluding tobacco-related disorders) according to DSM-5 diagnostic criteria.\n* Participants diagnosed with eating disorders and feeding disorders according to DSM-5 diagnostic criteria.\n* Participants who show a positive reaction in alcohol tests or urine drug tests at screening.\n* Participants with complications or a history of the following neurological disorders:\n\n  * Epilepsy\n  * Seizures (other than infantile febrile seizures)\n  * Syncope\n  * Tourette's disorder\n  * History of significant head trauma with clinically significant loss of consciousness\n  * Dementia\n  * Cerebrovascular disease\n  * Parkinson's disease\n  * Intracranial lesions\n  * Other severe neurological disorders\n* Participants with complications or a history of cardiovascular diseases.\n* Participants with clinical laboratory test results at screening that meet any of the following criteria:\n\n  * Platelets \\\u003C= 75,000\u002Fmm3\n  * Hemoglobin \\\u003C= 9 g\u002FdL\n  * Neutrophils, absolute \\\u003C= 1000\u002Fmm3\n  * AST \\> 2 x ULN\n  * ALT \\> 2 x ULN\n  * Creatinine \\>= 2 mg\u002FdL\n  * CPK \\>= 2 x ULN (except for the cases that the medical monitor determined that participant's inclusion is possible based on the discussion about the participant's condition with the investigator or subinvestigator) •Abnormal values for both free T4 and TSH•\n* Participants who cannot agree to discontinuation of prohibited concomitant medication, such as ADHD medication or antidepressants.",{"count":340,"type":21},630,[342,320],"PHASE2","The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.",[27],{"date":325,"type":36},{"date":347,"type":36},"2025-04-30",{"date":329,"type":21},{"name":331,"class":97},{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":53,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":369,"leadSponsor":371,"locationsCount":44},"100595205","effectiveness-of-manual-therapy-in-the-treatment-of-attention-deficit-hyperactivity-disorder-100595205","NCT07029425","Effectiveness of Manual Therapy in the Treatment of Attention Deficit Hyperactivity Disorder","MT-ADHD","Inclusion Criteria:\n\n* Confirmed ADHD diagnosis according to DSM-5 criteria.\n* Children and adolescents aged 6 to 12 years.\n* Availability to attend all Manual Therapy (MT) sessions.\n* Informed consent signed by legal guardians.\n\nExclusion Criteria:\n\n* Severe concomitant psychiatric or neurological disorders (e.g., epilepsy, severe autism spectrum disorder, schizophrenia).\n* Medical conditions that contraindicate MT (e.g., fractures, severe scoliosis, connective tissue diseases).\n* Recent use of or changes in ADHD medication within the past 4 weeks.\n* Simultaneous participation in other interventional studies.",{"count":358,"type":21},60,[24],"The main objective is to determine whether Manual Therapy (MT), in addition to conventional treatment, is more effective in improving ADHD symptoms than the application of conventional treatment alone.",[27],[189,363,364],"manual therapy","pediatrics","2025-06-24",{"date":367,"type":36},"2025-06-27",{"date":196,"type":21},{"date":370,"type":21},"2026-06-30",{"name":372,"class":43},"JJ JIMENEZ-REJANO",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":44},"100582070","deficit-hyperactivity-disorder--substance-use-disorder-comorbidity-in-integrated-treatment-100582070","NCT06858527","Deficit Hyperactivity Disorder \u002F Substance Use Disorder Comorbidity in Integrated Treatment","Adults With Attention Deficit Hyperactivity Disorder \u002F Substance Use Disorder Comorbidity in Integrated Treatment: Effectiveness and Feasibility","ATTenTIFF","Inclusion Criteria:\n\n* Age 18 or older ;\n* Suffer from at least one moderate to severe SUD regarding the DSM-5 (tobacco excluded) ;\n* Being currently treated for a SUD by a physician of a psychologist ;\n* Being diagnosed with an ADHD according to the DIVA 2.0 of DIVA-5 ;\n* Being affiliated to a health insurance ;\n* Understanding and being able to express himselves in French\n* Signed consent\n\nExclusion Criteria:\n\n* Age under 18;\n* Pregnant or breastfeeding women;\n* Not having sign the consent form;\n* Major difficulties in understanding and\u002For expressing themselves in french;\n* Severe cognitive impairment;\n* Acute medical condition making assessment impossible and\u002For contraindicating participation in group intervention;\n* Substance use disorder in a protected environment, currentlu or in the last 15 days, or expected during the study;\n* No substance use disorder other than tobacco use disorder;\n* Persons under guardianship;\n* Participant deprived of liberty or under penal care orders;\n* Participation in another group psychotherapeutic intervention throughout the duration of the intervention",{"count":382,"type":21},132,[24],"Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs) is a highly common comorbid condition associated with serious medical and psychosocial consequences. However, and despite the international consensus recommending integrated treatment for this comorbidity, few studies tested the efficacy of specific psychotherapeutic treatment for this comorbidity.\n\nThe aim of this study is to test the efficacy of a specific group Cognitive and Behavioral Therapy (CBT) for the treatment of adults with this comorbidity.\n\nThis is a longitudinal, randomized controlled intervention study utilizing a crossover design between the intervention and treatment-as-usual (TAU) waitlist condition, aimed at testing the effectiveness of an integrated psychotherapeutic group treatment for adults with comorbid Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs).",[27,386],"Substance-related Disorder",[189,388,389,390,391],"Substance-Related Disorders","Cognitive Behavioral Therapy","Dual Diagnosis","Randomized Controlled Trial","2025-06-23",{"date":394,"type":36},"2025-06-26",{"date":396,"type":36},"2025-04-01",{"date":398,"type":21},"2029-07",{"name":400,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":53,"enrollmentInfo":407,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":411,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":418,"locationsCount":4},"100589165","home-based-executive-function-training-intervention-for-attention-deficit-hyperactivity-disorder-prone-children-100589165","NCT06950866","Home-Based Executive Function Training Intervention For Attention-Deficit\u002F Hyperactivity Disorder-prone Children","Inclusion Criteria:\n\n* 1.SNAP-IV scale, inattention or hyperactivity-impulsivity scale score \\> 1.2\n* 2.Parents who could understand or lacking of access to computers and the Internet\n* 3.Parents can commit to ensuring full participation and complete the training and test evaluations in full compliance with the researcher's requirements\n* 4.Children and their parents consent to the study\n\nExclusion Criteria:\n\n* 1.Children or parents with severe organic encephalopathy and other severe mental disorders\n* 2.Parents or children are receiving ADHD-related behavioral treatment\n* 3.Parents or children who dropped out before the study started or in the middle of the study",{"count":265,"type":21},[24],"This study aims to investigate the effectiveness of a home-based executive function training Intervention on children's ADHD symptoms, executive function and parents' parenting stress.",[27],[27,412],"Executive function training","2025-04-22",{"date":347,"type":36},{"date":416,"type":21},"2025-05-01",{"date":304,"type":21},{"name":419,"class":43},"Wuhan Mental Health Centre",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":105,"enrollmentInfo":427,"targetDuration":4,"studyType":22,"phases":429,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":440,"leadSponsor":442,"locationsCount":44},"100557771","phase-2-the-safety-and-efficacy-of-terpene-enriched-cannabidiol-cbd-oil-in-adhd-100557771","NCT06542445","The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD","The Safety and Efficacy of Treatment With Cannabidiol (CBD) Oil Enriched With Terpenes, Devoid of THC, in Children Diagnosed With ADHD","Inclusion Criteria:\n\n1. Children\u002Fadolescents aged 6-18 diagnosed with ADHD as per DSM-V by a neurologist, psychiatrist or other specialist.\n2. Willing\u002Fable to arrive to all the necessary visits as per study protocol.\n\nExclusion Criteria:\n\n1. Participants who used ADHD conventional medications in the month before starting the study or intend to do so during the study.\n2. Participants who used benzodiazepines or first-generation antihistamines in the week before starting the study or other drugs which may interfere with the study as per PI opinion.\n3. Participants suffering from neurological or psychiatric diseases.\n4. Participants suffering from neoplastic diseases.\n5. Participants with syndromes or metabolic diseases.\n6. Participants with a significant clinic diagnosis which may interfere with the study. May be included later on as per PI opinion.\n7. Pregnant or breastfeeding adolescents.\n8. Sexually active female adolescents who are unwilling to use contraceptives.\n9. Participants that in the PI opinion will not comply with the protocol in a way that will harm the study (for ex.: not using contraceptives.)\n10. Participants with less than 18 kg or more than 90 kg weight.\n11. Participants with BMI lower than 18 or higher than 29.9.\n12. Participants engaged in another clinical study which includes a medicine.\n13. Participants engaged in another study regarding ADHD treatment of any kind.\n14. Participants using alcohol or drugs.\n15. Past or present use of Cannabis, including medical cannabis\n\nCriteria for early termination:\n\n1. Use of another medication for ADHD during the study.\n2. Use of a medication from the exclusion criteria list during the study.\n3. Use of alcohol or drugs during the study.\n4. Participants who got pregnant during the study.\n5. Participants who split the first visit and did not arrive to the second part of the first visit after a maximum of 28 days.\n6. Participants who did not start the treatment during the 14 days from receiving the drug.\n7. Non -compliant participants.\n\nCriteria for exchange:\n\n1. PI may exchange participants that quit, if they did not start treatment for new participants.\n2. PI may recruit again participants who quit after a new full recruitment process.",{"count":428,"type":21},120,[342],"ADHD is the most frequent neurodevelopmental disorder in childhood. Symptoms often appear in preschool years, and most children (65-80%) continue to experience some ADHD-associated symptoms into adolescence and adulthood. The disorder is marked by age-inappropriate inattention, hyperactivity, and impulsivity. Drug treatments for ADHD include stimulants containing methylphenidate (like Ritalin and Concerta) or amphetamines (like Vyvanse). However, 30-35% of the patients do not respond well to these treatments, and stimulants may result with various side effects.\n\nThe use of medical cannabis increases; applied for expending medical conditions, with growing evidence for its beneficial effects. A study on ADHD adults treated by cannabinoids demonstrated improvements in hyperactivity and impulsivity.\n\nThe current study is aimed to examine the safety and efficacy of treating children diagnosed with ADHD with a CBD oil (devoid of THC), enriched with terpenes. Participants will be randomly assigned to receive either the enriched CBD oil or a placebo, for 5 weeks (Treatment, Stage I).\n\nAt the end of the treatment stage (I), an open-label stage will follow (II), wherein, all participants will receive the investigational product for an additional 5 weeks.\n\nThe investigators hypothesize that children treated with the enriched CBD oil (Treatment, Stage I) will show significantly higher improvement in hyperactivity and inattention scores, as compared with the placebo group.",[27],[433,434,435,189],"Cannabidiol","Terpenes","Medical Cannabis","2024-08-22",{"date":438,"type":36},"2024-08-23",{"date":436,"type":36},{"date":441,"type":21},"2026-09-22",{"name":443,"class":97},"Bazelet Nehushtan LtD."]